慢性鼻炎的生物制剂:当前和未来。

IF 2.7 3区 医学 Q2 ALLERGY Immunology and Allergy Clinics of North America Pub Date : 2024-08-17 DOI:10.1016/j.iac.2024.07.005
{"title":"慢性鼻炎的生物制剂:当前和未来。","authors":"","doi":"10.1016/j.iac.2024.07.005","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":54997,"journal":{"name":"Immunology and Allergy Clinics of North America","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biologics in Chronic Rhinosinusitis\",\"authors\":\"\",\"doi\":\"10.1016/j.iac.2024.07.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":54997,\"journal\":{\"name\":\"Immunology and Allergy Clinics of North America\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-08-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunology and Allergy Clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0889856124000547\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology and Allergy Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889856124000547","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

慢性鼻窦炎(CRS)从表型上可分为有鼻息肉和无鼻息肉型(CRSwNP、CRSsNP)。内型根据免疫细胞活性和炎症机制将疾病分为 1 型、2 型和 3 型。研究最多的是 2 型内型,它与哮喘、特应性疾病和严重的 CRSwNP 有关。对于 CRSwNP 控制不佳的患者,目前有 3 种已获批准的生物制剂治疗方法:奥马珠单抗(omalizumab)、杜匹单抗(dupilumab)和美博利珠单抗(mepolizumab)。许多其他生物制剂正在针对 CRSwNP 和 CRSsNP 的 2 型、非 2 型和混合内型进行测试。这些研究将在塑造 CRS 管理的未来方面发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Biologics in Chronic Rhinosinusitis
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.40
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.
期刊最新文献
Contents Asthma Biologics Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma Biologics in Allergic/Immunologic Conditions Copyright
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1